Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2009-07-25 00:07:32 UTC |
---|
Update Date | 2021-09-14 15:40:56 UTC |
---|
HMDB ID | HMDB0012798 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | 5'-Carboxy-alpha-chromanol |
---|
Description | 5'-carboxy-alpha-tocopherol is a dehydrogenation carboxylate product of 5'-hydroxy-a-tocopherol by an unidentified microsomal enzyme(s) probably via an aldehyde intermediate. The tocopherols ( a-tocopherol , b-tocopherol ,r-tocopherol and d-tocopherol ) and their corresponding tocotrienols are synthesized by plants and have vitamin E antixoidant activity (see pathway vitamin E biosynthesis ). They differ in the number and location of methyl groups on the chromanol ring. The naturally occurring form of a-tocopherol is (2R,4'R,8'R)-a-tocopherol (synonym (R,R,R)-a-tocopherol). Synthetic a-tocopherols are a racemic mixture of eight different R and S stereoisomers. Only the 2R forms are recognized as meeting human requirements. The in vivo function of vitamin E is to scavenge peroxyl radicals via its phenolic (chromanol) hydroxyl group, thus protecting lipids against free radical-catalyzed peroxidation. The tocopheryl radical formed can then be reduced by reductants such as L-ascorbate. Other major products of a-tocopherol oxidation include α-tocopherylquinone and epoxy-a-tocopherols. The metabolites a-tocopheronic acid and its lactone, known as the Simon metabolites, are generally believed to be artefacts. In addition to these oxidation products, the other major class of tocopherol metabolites is the carboxyethyl-hydroxychromans.These metabolites are produced in significant amounts in response to excess vitamin E ingestion. Vitamin E is fat-soluble and its utilization requires intestinal fat absorption mechanisms. It is secreted from the intestine into the lymphatic system in chylomicrons which subsequently enter the plasma. Lipolysis of these chylomicrons can result in delivery of vitamin E to tissues, transfer to high-density lipoproteins (and subsequently to other lipoproteins via the phospholipid exchange protein), or retention in chylomicron remnants. These remnants are taken up by the liver. Natural (R,R,R)-α-tocopherol and synthetic 2R-α-tocopherols are then preferentially secreted from the liver into plasma as a result of the specificity of the α-tocopherol transfer protein. This protein, along with the metabolism of excess vitamin E in the liver and excretion into urine and bile, mediate the supply of a-tocopherol in plasma and tissues. |
---|
Structure | CC(CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C)C(O)=O InChI=1S/C19H28O4/c1-11(18(21)22)7-6-9-19(5)10-8-15-14(4)16(20)12(2)13(3)17(15)23-19/h11,20H,6-10H2,1-5H3,(H,21,22)/t11?,19-/m1/s1 |
---|
Synonyms | Value | Source |
---|
alpha-CMBHC | MeSH | 5'-Carboxy-alpha-tocopherol | HMDB | 5-[(2R)-6-Hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl]-2-methylpentanoate | Generator |
|
---|
Chemical Formula | C19H28O4 |
---|
Average Molecular Weight | 320.4232 |
---|
Monoisotopic Molecular Weight | 320.198759384 |
---|
IUPAC Name | 5-[(2R)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl]-2-methylpentanoic acid |
---|
Traditional Name | 5-[(2R)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-1-benzopyran-2-yl]-2-methylpentanoic acid |
---|
CAS Registry Number | Not Available |
---|
SMILES | CC(CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C)C(O)=O |
---|
InChI Identifier | InChI=1S/C19H28O4/c1-11(18(21)22)7-6-9-19(5)10-8-15-14(4)16(20)12(2)13(3)17(15)23-19/h11,20H,6-10H2,1-5H3,(H,21,22)/t11?,19-/m1/s1 |
---|
InChI Key | QWPNLVBAEZJBMI-IMFVZPHKSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 1-benzopyrans. These are organic aromatic compounds that 1-benzopyran, a bicyclic compound made up of a benzene ring fused to a pyran, so that the oxygen atom is at the 1-position. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzopyrans |
---|
Sub Class | 1-benzopyrans |
---|
Direct Parent | 1-benzopyrans |
---|
Alternative Parents | |
---|
Substituents | - 1-benzopyran
- Medium-chain fatty acid
- Alkyl aryl ether
- Branched fatty acid
- Heterocyclic fatty acid
- Hydroxy fatty acid
- Methyl-branched fatty acid
- Fatty acyl
- Fatty acid
- Benzenoid
- Carboxylic acid derivative
- Carboxylic acid
- Ether
- Oxacycle
- Monocarboxylic acid or derivatives
- Organic oxide
- Hydrocarbon derivative
- Carbonyl group
- Organic oxygen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
5'-Carboxy-alpha-chromanol,1TMS,isomer #1 | CC1=C(C)C2=C(CC[C@@](C)(CCCC(C)C(=O)O)O2)C(C)=C1O[Si](C)(C)C | 2586.7 | Semi standard non polar | 33892256 | 5'-Carboxy-alpha-chromanol,1TMS,isomer #2 | CC1=C(C)C2=C(CC[C@@](C)(CCCC(C)C(=O)O[Si](C)(C)C)O2)C(C)=C1O | 2490.7 | Semi standard non polar | 33892256 | 5'-Carboxy-alpha-chromanol,2TMS,isomer #1 | CC1=C(C)C2=C(CC[C@@](C)(CCCC(C)C(=O)O[Si](C)(C)C)O2)C(C)=C1O[Si](C)(C)C | 2561.8 | Semi standard non polar | 33892256 | 5'-Carboxy-alpha-chromanol,1TBDMS,isomer #1 | CC1=C(C)C2=C(CC[C@@](C)(CCCC(C)C(=O)O)O2)C(C)=C1O[Si](C)(C)C(C)(C)C | 2832.3 | Semi standard non polar | 33892256 | 5'-Carboxy-alpha-chromanol,1TBDMS,isomer #2 | CC1=C(C)C2=C(CC[C@@](C)(CCCC(C)C(=O)O[Si](C)(C)C(C)(C)C)O2)C(C)=C1O | 2765.8 | Semi standard non polar | 33892256 | 5'-Carboxy-alpha-chromanol,2TBDMS,isomer #1 | CC1=C(C)C2=C(CC[C@@](C)(CCCC(C)C(=O)O[Si](C)(C)C(C)(C)C)O2)C(C)=C1O[Si](C)(C)C(C)(C)C | 3023.7 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - 5'-Carboxy-alpha-chromanol GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a59-5193000000-21a44421397f44e8ef10 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 5'-Carboxy-alpha-chromanol GC-MS (2 TMS) - 70eV, Positive | splash10-0092-9418400000-1183546d2d9264c18b03 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 5'-Carboxy-alpha-chromanol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 10V, Positive-QTOF | splash10-0g4i-0739000000-ca7cf4a3acdfe0598353 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 20V, Positive-QTOF | splash10-014i-1911000000-87257705b965ee40a7b5 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 40V, Positive-QTOF | splash10-066r-3900000000-51c6445c30175ea5c865 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 10V, Negative-QTOF | splash10-014i-0019000000-e48de0e905548411c044 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 20V, Negative-QTOF | splash10-0i29-1798000000-b5d9e37b42b4c3fd9889 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 40V, Negative-QTOF | splash10-0r7j-3920000000-36465eb352f634a1d51b | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 10V, Negative-QTOF | splash10-014i-0019000000-03b18204386c4c9d8bd4 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 20V, Negative-QTOF | splash10-016r-0395000000-2bf38f23f39a4fa97197 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 40V, Negative-QTOF | splash10-0a4r-0690000000-539dacc450e163bec4e1 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 10V, Positive-QTOF | splash10-0fi0-0096000000-6c33505488ad70d71925 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 20V, Positive-QTOF | splash10-004j-0090000000-366d350d1a77109facef | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5'-Carboxy-alpha-chromanol 40V, Positive-QTOF | splash10-014i-4920000000-158de22677ca15ece6b9 | 2021-09-23 | Wishart Lab | View Spectrum |
|
---|
Disease References | Iron deficiency |
---|
- Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4. [PubMed:26848182 ]
| Ulcerative colitis |
---|
- Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4. [PubMed:26848182 ]
|
|
---|